# A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)

> **NCT07015983** · PHASE2 · RECRUITING · sponsor: **Juno Therapeutics, Inc., a Bristol-Myers Squibb Company** · enrollment: 89 (estimated)

## Conditions studied

- Lupus Erythematosus, Systemic
- Lupus Nephritis

## Interventions

- **DRUG:** CC-97540
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT07015983
- **Lead sponsor:** Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-14
- **Primary completion:** 2028-05-17
- **Final completion:** 2032-06-15
- **Target enrollment:** 89 (ESTIMATED)
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07015983

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07015983, "A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT07015983. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*